Soleno Therapeutics Inc (NAS:SLNO)

$ 52.7 -0.94 (-1.75%) Market Cap: 2.05 Bil Enterprise Value: 1.82 Bil PE Ratio: 0 PB Ratio: 7.21 GF Score: 38/100

Soleno Therapeutics Inc Randomized Withdrawal Period of Study C602 Topline Results Call Transcript
Sep 26, 2023
Soleno Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Soleno Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 03, 2023
Soleno Therapeutics Inc at Destiny-PWS Transcript
Oct 20, 2020

Soleno Therapeutics Inc at Destiny-PWS Transcript

Oct 20, 2020 / NTS GMT

Release Date Price: $28.05

Transcript

Susan Hedstrom

Foundation for Prader-Willi Research - Moderator

Welcome, everyone, to today's presentation. I love how those of you who have been joining us on previous sessions today recognize that the music was not playing on that video. I love listening to that video. Every time I watch it, it almost brings tears to my eyes because it reminds me of how much our community and our kids are working together to find treatments for PWS. And that's why I'm so thrilled to have today's presentation, which is a return of results presentation.

So to kick off today's session, I would like to present to you, Anish Bhatnagar, CEO of Soleno Therapeutics.

Anish Bhatnagar

Soleno Therapeutics Inc. - CEO

Thank you, Susan. My name is Anish Bhatnagar. I'm the CEO of Soleno Therapeutics. Also one of the physicians involved in the DCCR development program at the company. I'm really thankful to FPWR for giving us the opportunity to speak here today. And also, shoutout to Susan for the amazing job she's doing keeping this train running. It's a challenging time with all of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.